Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against Alvotech for possible violations of federal securities laws and unlawful business practices [1][2] - Alvotech's stock experienced a significant decline of 34.25%, dropping $2.62 to close at $5.03 per share following a Complete Response Letter from the FDA regarding its AVT05 BLA biologics license application [2] Investigation Details - The investigation was prompted by a failed facility inspection in July 2025, which led to the FDA's Complete Response Letter received on November 3, 2025 [2] - Investors who suffered losses and have information regarding Alvotech are encouraged to contact the law firm for further discussion on their rights and potential claims [3] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation [4] - The firm operates in multiple states, including New York, South Carolina, and California, and offers services without cost or obligation to the investors [4]

Core Insights - Holzer & Holzer, LLC is investigating uniQure N.V. for potential compliance issues with federal securities laws following a recent FDA meeting [1] - uniQure disclosed that the FDA no longer agrees that data from Phase I/II studies of AMT-130 may be adequate for a Biologics License Application submission [1] - The announcement led to a decline in uniQure's stock price [1] Company Summary - uniQure N.V. is involved in the development of gene therapies, specifically AMT-130, which is under scrutiny due to regulatory feedback from the FDA [1] - The company had a pre-BLA meeting with the FDA, which raised concerns about the adequacy of its clinical data [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation and is reaching out to investors who may have suffered losses due to the recent developments with uniQure [2][3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options To learn more about the Tvardi investigation, go to www.faruqilaw.com/TVRD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of violations of federal securities laws, particularly following disappointing clinical trial results that led to a significant drop in the company's stock price [2][3][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1][2]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives made false or misleading statements regarding the efficacy of their product SLK compared to BIMZELX, including claims about molecular targets and clinical benefits [3]. - Specific allegations include that SLK shares the same molecular targets as BIMZELX and that its unique structure does not provide superior clinical benefits [3]. Group 3: Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - A federal securities class action lawsuit has been filed against DexCom, Inc. for alleged violations of federal securities laws, primarily related to misleading statements and undisclosed product issues with its G6 and G7 glucose monitoring devices [1][6]. Key Events - **FDA Warning Letter (March 10, 2025)**: The FDA issued a Warning Letter indicating that DexCom had "adulterated" its G6 and G7 sensors by modifying them without prior approval, leading to inaccuracies and health risks. Following this, the stock dropped by $7.12 (−9.15%) to $70.72 [2]. - **Public Disclosure (March 25-26, 2025)**: The FDA published the Warning Letter on its website, confirming product issues, which caused the stock to fall another $3.19 (−4.24%) to $72.13 [2]. - **Oppenheimer Downgrade (September 8, 2025)**: Oppenheimer downgraded DexCom from "outperform" to "perform" due to rising patient concerns over G7 sensor accuracy, resulting in a stock decline of $2.51 (−3.12%) to $78.00 [2]. - **Hunterbrook Report (September 18, 2025)**: A report titled "DexCom's Fatal Flaws" revealed that G7 devices caused hospitalizations and deaths due to inaccurate readings, leading to a stock plunge of $8.99 (−11.76%) to $67.45 over two sessions [2]. Allegations Against DexCom - DexCom allegedly made material design changes to its G6 and G7 devices without FDA authorization, compromising reliability and posing health risks [6]. - The company is accused of overstating the reliability, accuracy, and functionality of the G7 device while downplaying the severity of the issues [6]. - DexCom faces increased risks of regulatory scrutiny, enforcement actions, and financial harm due to these allegations [6]. Next Steps for Investors - Investors who acquired DexCom securities during the class period (July 26, 2024 – September 17, 2025) may move the Court to be appointed lead plaintiff by December 26, 2025 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the efficacy of its drug Efzofitimod, which led to inflated stock prices [3][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1][5]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives made false and misleading statements regarding the drug Efzofitimod, particularly about its ability to allow patients to taper off steroid usage [3]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [4]. - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from $6.03 on September 12 to $1.01 on September 15 [4].

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial outlook during the Class Period from February 27, 2025, to August 11, 2025 [6]. Allegation Details - The lawsuit claims that PubMatic failed to disclose significant adverse facts, including a top Demand-Side Platform (DSP) buyer shifting clients to a new platform, resulting in reduced ad spend and revenue for PubMatic [6]. - The complaint highlights that the positive statements made by PubMatic regarding its business were misleading and lacked a reasonable basis due to these undisclosed issues [6]. Financial Impact - Following the release of its second quarter 2025 financial report on August 11, 2025, which revealed a reduction in ad spend from a top DSP partner, PubMatic's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [6].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company that provides managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was able to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding a challenging medical cost trend environment, Molina's stock price fell by $32.03 per share, or 16.8%, from $190.25 to $158.22 [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against J.M. Smucker Company for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on the financial performance and business practices of Smucker, particularly following significant impairment charges and disappointing sales results in its Sweet Baked Snacks segment [6]. Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [6]. - On February 27, 2025, Smucker reported a Q3 2025 net sales decrease of 8% in Sweet Baked Snacks, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [6]. - On June 10, 2025, the company announced a Q4 2025 net sales decrease of 14% in Sweet Baked Snacks, with an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [6]. - Following these announcements, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share on June 10, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that during the class period from March 7, 2024, to May 23, 2025, Savara did not disclose that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely [8]. - The complaint also states that the delay in regulatory approval would likely necessitate Savara to raise additional capital [8]. - Following the announcement of a refusal to file letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [8]. Next Steps - Investors who purchased Savara shares and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 7, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].